TRIAL BY JURY: Irritable Bowel Syndrome

Irritable Bowel Syndrome

Program Information

Target Audience:

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with irritable bowel syndrome (IBS).

Educational Objectives

After completing this program, participants should be better able to:

Design treatment plans for patients with IBS that are aligned with current evidence-based recommendations

Explain the quality of evidence, magnitude of benefit, safety, and tolerability of specific treatments for IBS

Incorporate new IBS therapies effectively into clinical practice


Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Cincinnati and the Gi Health Foundation.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:

All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, the Gi Health Foundation staff and the University of Cincinnati staff have no relationships to disclose.

Learner Assurance Statement

The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Americans with Disabilities Act

The event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact us prior to the event at 1-877-782-4532.

Accredited by

Provided by


Supported by educational grant from Salix Pharmaceuticals.

This program is neither sponsored nor endorsed by ACG.

Sunday, October 27, 2019

Registration: 5:30 AM
Breakfast & CME Symposium: 6:00 – 7:30 AM
Grand Hyatt San Antonio
Lone Star Ballroom (ABC – 2nd Floor)
600 E. Market Street
San Antonio, TX 78205




JUDGE
Brooks D. Cash, MD, FACG
Dan and Lillie Sterling Professor of Medicine
Chief, Gastroenterology, Hepatology, and Nutrition
UT Health Science Center at Houston
Houston, Texas
 
PROSECUTION, DEFENSE, AND EXPERT WITNESSES

Lin Chang, MD
Professor of Medicine
Vice-Chief, Vatche and Tamar
Manoukian Division of Digestive Diseases
David Geffen School of Medicine at UCLA
Los Angeles, California
William D. Chey, MD, FACG,
AGAF, FACP, RFF
Director, GI Physiology Lab
Director, Nutrition & Lifestyle Program
Michigan Medicine
Ann Arbor, Michigan

David C. Kunkel, MD
Assistant Clinical Professor of Medicine
GI Motility and Physiology Program
Division of Gastroenterology
University of California
San Diego, California
Mark Pimentel, MD,FRCP(C)
Executive Director, Medically Associated
Science and Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Associate Professor of Medicine, Cedars-Sinai
Cedars-Sinai Medical Center
Los Angeles, California
AGENDA
 
5:30 AM Registration, Seating, and Buffet
 
6:00 AM Judge’s Opening Remarks and Preliminary Instructions
 
6:05 AM TRIAL IN SESSION WITH EXPERT ARGUMENTS:
Current Controversies in IBS Management
Opening Statement / Plaintiff’s Case / Defendant’s Case
 
7:15 AM Closing Statements and Jury Vote
 
7:20 AM Verdict Summary, Panel Discussion, and Q&A
 
7:30 AM Adjournment
 
 
Back to Overview

Lin Chang, MD
Professor of Medicine
Vice-Chief, Vatche and Tamar
Manoukian Division of Digestive Diseases
David Geffen School of Medicine at UCLA
Los Angeles, California
Lin Chang, MD is a Professor of Medicine and Vice-Chief of the Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine at the David Geffen School of Medicine at UCLA. She serves as the Co-Director of the G. Oppenheimer Center for Neurobiology of Stress and Resilience at UCLA. She is also Program Director of the UCLA Gastroenterology Fellowship Program. Dr. Chang’s clinical expertise is in functional gastrointestinal disorders. Her research focuses on brain-gut interactions underlying irritable bowel syndrome (IBS), specifically, the pathophysiology of IBS related to stress, early life adversity, sex differences, genetic and epigenetic factors, and gut microbiome and the treatment of IBS.

She is a fellow of the American College of Gastroenterology and the American Gastroenterological Association (AGA). She is currently the Clinical Research Councilor of the AGA Governing Board. She previously served as President of the American Neurogastroenterology and Motility Society (ANMS) and is a member of the Rome Foundation Board of Directors. She has authored more than 130 original research articles, 60 review articles, and 25 book chapters on her specialty interests.

SPEAKER DISCLOSURES:

Scientific Advisory Board: Arena, Alnylam, IM Health Sciences, Ironwood, and OrphoMed
Scientific Advisory Board and Speaker: Shire-Takeda.
Consultant: Allergan.
Stock Options: Metame, Modify Health.
Research Support: Alnylam, Vanda.
Back to Overview

William D. Chey, MD, FACG,
AGAF, FACP, RFF
Timothy T. Nostrant Collegiate Professor of Gastroenterology
Director, GI Physiology Laboratory
Director, Digestive Disorders Nutrition & Behavioral Health Program
Director, Michigan Food for Life Kitchen
Medical Director, Michigan Bowel Control Program
Division of Gastroenterology
Departments of Internal Medicine and Nutritional Sciences
Michigan Medicine
Ann Arbor, Michigan
Dr Chey received his BA degree from the University of Pennsylvania and medical degree & training in internal medicine at Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained as faculty at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He was awarded a joint appointment in the Department of Nutrition Sciences in 2015.

His research interests focus on the diagnosis & treatment of functional bowel disorders, acid-related disorders, and H. pylori infection. He is a medical innovator and holds 3 patents. He co-founded "My Total Health" https://mygihealth.io/), a company developing novel health information technology solutions for persons with GI problems.

Dr Chey has authored more than 300 manuscripts, reviews, chapters & books. He served as Co-editor-in-Chief of the American Journal of Gastroenterology (2010-2015), founding co-Editor of Clinical & Translational Gastroenterology (2011-2014). He led the ACG H. pylori practice guideline published in the American Journal of Gastroenterology in 2017. He served on the Editorial Board for the Rome IV criteria for the functional GI disorders published in 2016. He is a member of the ACG IBS Task Force responsible for the evidence-based monograph published in 2018. He is working with the ACG, AGA and CAG on 3 additional clinical practice guidelines.

Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology, Board of Directors of the Rome Foundation, and Council of the American Neurogastroenterology & Motility Society. He is Scientific Advisor for the International Foundation of Functional GI Disorders.

He has been elected to "Best Doctors" since 2001, "America's Top Doctors" since 2009, and repeatedly named as one of the Top Gastroenterologists in Detroit. He has received the Dean’s Outstanding Clinician Award and the Dean's Award for Innovation & Commercialization at the University of Michigan and the Distinguished Clinician Award from the American Gastroenterological Association. He is past President of the Clinical Excellence Society in the Department of Medicine at Michigan Medicine.

SPEAKER DISCLOSURES:

Consultant: Allergan, Biomerica, IM Health, Ironwood, Outpost, QOL Medical, Ritter, Salix/Valeant, Takeda, and Urovant.
Grant Funding: Biomerica, Commonwealth, Ironwood, Nestle, QOL Medical, Salix, Urovant, and Zespri.
Back to Overview

David C. Kunkel, MD
Assistant Clinical Professor of Medicine
GI Motility and Physiology Program
Division of Gastroenterology
University of California
La Jolla, California
David Kunkel is an assistant professor and co-director of the GI motility and physiology program at the University of California, San Diego. Dr. Kunkel’s research interests span both motility and functional bowel disorders. Dr. Kunkel is a co-investigator on an NIH-sponsored study to develop new treatment strategies for fecal incontinence. He is co-founder of the GI Innovation Group at UCSD, which has developed a wearable biosensor to monitor stomach myoelectrical activity. He is also actively involved in the development of clinical trial agents to treat IBS.

SPEAKER DISCLOSURES:

Consultant: Allergan and Arena Pharmaceuticals.
Back to Overview

Mark Pimentel, MD,FRCP(C)
Executive Director, Medically Associated
Science and Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Associate Professor of Medicine, Cedars-Sinai
Cedars-Sinai Medical Center
Los Angeles, California
Mark Pimentel, M.D., is Professor of Medicine, Geffen School of Medicine and Associate Professor at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Pimentel completed 3 years of an undergraduate degree in honors microbiology and biochemistry at the University of Manitoba, Canada. This was followed by his medical degree, and his BSc (Med) from the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada, where he also completed a residency in internal medicine. His medical training includes a fellowship in gastroenterology at the UCLA Affiliated Training Program. Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Physiology, American Journal of Medicine, American Journal of Gastroenterology and Digestive Diseases and Sciences, among others. Dr. Pimentel has been invited to present his work at meetings, grand rounds, and advisory boards in the United States and Internationally. He is diplomate of the American Board of Internal Medicine (Gastroenterology) and a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Pimentel is also a member of several medical associations including the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.

A few of Dr. Pimentel's most significant accomplishments include:
1. The discovery of rifaximin as a treatment for irritable bowel syndrome (IBS)
2. He developed the first blood test for IBS on the basis of IBS being derived from acute gastroenteritis
3. Described the association between IBS and bacterial overgrowth which forms the basis for microbiome therapies in this condition
4. Uncovered the methanogen (M. smithii) as an agent for causing constipation in humans.
5. Discovered the use of lovastatin as a microbiome treatment for constipation on the basis of inhibiting methane production by methanogens

SPEAKER DISCLOSURES:

Grants, Licensing, Cedar Consultant: Salix Pharmaceuticals and Bausch Health.
Grant, Equity, Consultant: Synthetic Biologics, Inc.
Board Equity, Cedars has licensing: Gemelli Biotech.
Consultant, Equity, Cedars has licensing: Naia.
Other Financial Material Support: Cedars-Sinai has licensing agreements with 2 companies above.
Back to Overview

Brooks D. Cash, MD, FACG
Dan and Lillie Sterling Professor of Medicine
Chief, Gastroenterology, Hepatology, and Nutrition
UT Health Science Center at Houston
Houston, Texas
Brooks D. Cash, MD, is the Chief of the Gastroenterology Division at UT Health Science Center and Co-director of the Ertan Digestive Disease Center at Memorial Herman. He holds the rank of Professor of Medicine at UT McGovern Medical School as well as Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. Board certified in Gastroenterology, his professional excellence has resulted in his election to fellowship in the American College of Physicians, the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. Dr. Cash served for 24 years in the US Navy, retiring in 2013 at the rank of Navy Captain. While in the Navy he served as Chief of Gastroenterology, Chief of Medicine, and Deputy Commander for Medicine at Bethesda Naval Hospital and the Walter Reed Army Medical Center. His clinical duties included Gastroenterology Consultant to the US Navy Surgeon General, Attending Physician to Congress, and White House Medical Unit. Prior to joining UT in 2018 he was Chief of Gastroenterology at the University of South Alabama in Mobile, AL. A recognized international expert in the field of irritable bowel syndrome and other functional gastrointestinal disorders, he has chaired numerous professional society committees and meetings. Dr. Cash has served on the Rome Committee for Functional Gastrointestinal Disorders and has authored over 200 articles and book chapters on a wide variety of gastrointestinal topics to include irritable bowel syndrome and chronic constipation, opioid induced constipation, colorectal cancer screening, CT colonography, gastroesophageal reflux disease, Barrett’s esophagus, medical education techniques, and evidence-based medicine. Active in clinical research and education, he is an Associate Editor for the American Journal of Gastroenterology, an editorial board member and reviewer for multiple internal medicine and gastroenterology medical journals, and is a sought-after lecturer at national and international scientific meetings.

SPEAKER DISCLOSURES:

Consultant, Speaker: Allergan, Salix Pharmaceuticals, and Takeda.
Consultant: Arena Pharmaceuticals.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.